Chronic thromboembolic pulmonary hypertension and clot resolution after COVID-19-associated pulmonary embolism

TY - JOUR

T1 - Chronic thromboembolic pulmonary hypertension and clot resolution after COVID-19-associated pulmonary embolism

AU - de Jong, Cindy M. M.

AU - Visser, Chantal

AU - Bemelmans, Remy H. H.

AU - Boersma, Wim G.

AU - van den Borst, Bram

AU - Burggraaf, J. Louise I.

AU - Cannegieter, Suzanne C.

AU - ten Cate-Hoek, Arina J.

AU - Croles, F. Nanne

AU - Faber, Harald J.

AU - Faber, Laura M.

AU - Hellemons, Merel E.

AU - Hessels, Lisa M.

AU - Huisman, Menno V.

AU - Kamphuisen, Pieter W.

AU - Koster, Stephanie C. E.

AU - Kroft, Lucia J. M.

AU - van der Lee, Ivo

AU - Leentjens, Jenneke

AU - Meijer, Karina

AU - Ninaber, Maarten K.

AU - Sondermeijer, Brigitte M.

AU - Stads, Susanne

AU - Dutch COVID & Thrombosis Coalition investigators

AU - Vonk Noordegraaf, Anton

AU - Winckers, Kristien

AU - Kruip, Marieke J. H. A.

AU - Klok, Frederikus A.

N1 - Funding Information: Conflict of interest: M.E. Hellemons reports honoraria for lectures (unrestricted) from Boehringer Ingelheim and Pfizer. M.V. Huisman reports grants or contracts from the Dutch Heart Foundation, ZonMW, Bayer Health Care, Pfizer-BMS and Leo Pharma, all outside this work. J. Leentjens reports payments from BMS-Pfizer, consulting fees from Viatris, contracts from Synapse, all unrelated to this work and paid to her institution. K. Meijer reports speaker fees from Alexion, Bayer and CSL Behring, participation in trial steering committees for Bayer and AstraZeneca, consulting fees from Uniqure, participation in data monitoring and endpoint adjudication committee for Octapharma, all unrelated to this work and paid to her institution. M.J.H.A. Kruip reports grants from The Netherlands Organisation for Health Research and Development, the Dutch Thrombosis Association and Sobi, speaker fees from Sobi, Roche and BMS, all paid to her institution. F.A. Klok reports grants or contracts from Bayer, BMS, BSCI, MSD, Leo Pharma, Actelion, Pharm-X, The Netherlands Organisation for Health Research and Development, the Dutch Thrombosis Association, The Dutch Heart Foundation and the Horizon Europe Program, all unrelated to this work and paid to his institution. C.M.M. de Jong, C. Visser, R.H.H. Bemelmans, W.G. Boersma, B. van den Borst, J.L.I. Burggraaf, S.C. Cannegieter, A.J. ten Cate-Hoek, F.N. Croles, H.J. Faber, L.M. Faber, L.M. Hessels, P.W. Kamphuisen, S.C.E. Koster, L.J.M. Kroft, I. van der Lee, M.K. Ninaber, B.M. Sondermeijer, S. Stads, A. Vonk Noordegraaf and K. Winckers report no conflicts of interest related to this project. Funding Information: Support statement: The Dutch COVID & Thrombosis Coalition is supported by The Netherlands Organisation for Health Research and Development (ZonMw project number 10430012010004) and the Dutch Thrombosis Association (project number 2020_A). This study was supported by an unrestricted grant from Johnson & Johnson. Funding information for this article has been deposited with the Crossref Funder Registry.

PY - 2023/4/1

Y1 - 2023/4/1

UR - http://www.scopus.com/inward/record.url?scp=85153419895&partnerID=8YFLogxK

U2 - https://doi.org/10.1183/13993003.00171-2023

DO - https://doi.org/10.1183/13993003.00171-2023

M3 - Article

C2 - 37080574

SN - 0903-1936

VL - 61

JO - The European respiratory journal

JF - The European respiratory journal

IS - 4

M1 - 2300171

ER -